DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of colorectal cancer for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
DRG Epidemiology’s colorectal cancer forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with colorectal cancer per year?
- How will improvements in survival change the number of people diagnosed with colorectal cancer per year?
- How will the declining risk of recurrence change the number of first-line drug-treatment opportunities for colorectal cancer?
- How will the epidemiology of colorectal cancer be impacted in the countries with colorectal cancer screening programs?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of colorectal cancer over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following colorectal cancer subpopulations:
- Diagnosed incident cases of colon cancer by stage at diagnosis.
- Diagnosed incident cases of rectal cancer by stage at diagnosis.
- Diagnosed prevalent cases of colon cancer by drug-treatment status.
- Diagnosed prevalent cases of rectal cancer by drug-treatment status.
- First-line drug-treatable colorectal cancer population (mutated RAS) by treatment status.
- First-line drug-treatable colorectal cancer population (wild-type RAS) by treatment status.
- Second-line drug-treatable colorectal cancer population (mutated RAS) by treatment status.
- Second-line drug-treatable colorectal cancer population (wild-type RAS) by treatment status.
- … and many more (details available on request).
Note: Coverage may vary by country.
- Colorectal Cancer - Epidemiology - Middle East And Africa
Author(s): Narendra Parihar; Nishant Kumar, MPH
Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.
His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.
His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.